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STUDY PROTOCOL Open Access
Effects of magnesium citrate, magnesium
oxide and magnesium sulfate
supplementation on arterial stiffness in
healthy overweight individuals: a study
protocol for a randomized controlled trial
Joëlle C. Schutten1*, Peter J. Joris2, Ronald P. Mensink2, Richard M. Danel3, Frans Goorman4,
M. Rebecca Heiner-Fokkema5, Rinse K. Weersma6, Charlotte A. Keyzer1, Martin H. de Borst1 and
Stephan J. L. Bakker1
Abstract
Background: Arterial stiffness is closely related to the process of atherosclerosis, an independent cardiovascular risk
factor, and predictive of future cardiovascular events and mortality. Recently, we showed that magnesium citrate
supplementation results in a clinically relevant improvement of arterial stiffness. It remained unclear whether the
observed effect was due to magnesium or citrate, and whether other magnesium compounds may have similar
effects. Therefore, we aim to study the long-term effects of magnesium citrate, magnesium oxide and magnesium
sulfate on arterial stiffness. In addition, we aim to investigate possible underlying mechanisms, including changes
in blood pressure and changes in gut microbiota diversity.
Methods: In this randomized, double-blind, placebo-controlled trial, a total of 162 healthy overweight and slightly
obese men and women will be recruited. During a 24-week intervention, individuals will be randomized to receive:
magnesium citrate; magnesium oxide; magnesium sulfate (total daily dose of magnesium for each active treatment
450 mg); or placebo. The primary outcome of the study is arterial stiffness measured by the carotid–femoral pulse
wave velocity (PWVc–f), which is the gold standard for quantifying arterial stiffness. Secondary outcomes are office
blood pressure, measured by a continuous blood pressure monitoring device, and gut microbiota, measured in
fecal samples. Measurements will be performed at baseline and at weeks 2, 12 and 24.
Discussion: The present study is expected to provide evidence for the effects of different available magnesium
formulations (organic and inorganic) on well-established cardiovascular risk markers, including arterial stiffness and
blood pressure, as well as on the human gut microbiota. As such, the study may contribute to the primary prevention
of cardiovascular disease in slightly obese, but otherwise healthy, individuals.
Trial registration: ClinicalTrials.gov, NCT03632590. Retrospectively registered on 15 August 2018.
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Background
Magnesium is an essential mineral that acts as a cofactor
in hundreds of enzymatic reactions in the human body. It
is, therefore, not surprising that insufficient magnesium
intake has been associated with a wide variety of meta-
bolic disorders, such as insulin resistance, and common
diseases that may result from metabolic deregulations,
such as hypertension and ischemic heart disease [1–5].
Foods with relatively high magnesium contents include
whole grains, leafy green vegetables, legumes and nuts.
Arterial stiffness is closely related to the extent of
atherosclerosis [6], an independent cardiovascular risk
factor [7], and predictive of future cardiovascular events
and mortality [8]. The gold standard for quantifying ar-
terial stiffness is the carotid–femoral pulse wave velocity
(PWVc–f ), a noninvasive method that measures the propa-
gation of the forward pressure wave traveling along the
aorta [8]. Recently, we observed a significant reduction of
arterial stiffness, measured by the PWVc–f, after 24 weeks
of oral magnesium citrate supplementation (total daily
dose of 350mg) in the magnesium citrate group compared
with the placebo group (8.3m/s vs 9.1 m/s, respectively)
[9]. Although blood pressure is a major determinant of
arterial stiffness [10], we did not observe any change in
blood pressure. This lack of effect on blood pressure could
be due to the total daily dose, which may have been too
low to detect changes in blood pressure. A meta-analysis
by Kass et al. [11] indeed showed that supplementation of
> 370mg/day resulted in a more pronounced blood
pressure-lowering effect. In addition, we could not diffe-
rentiate whether the beneficial effect on arterial stiffness
was due to the supplementation of magnesium or due to
citrate. The mechanism by which magnesium decreases
arterial stiffness is not entirely known, but an effect on gut
microbiota has been observed [12–14]. Previous studies
have shown that magnesium deficient diets resulted in an
altered microbiome and, more specifically, decreased
microbial diversity in mice [13, 15, 16]. Gut microbiome
diversity has recently been shown to be inversely asso-
ciated with arterial stiffness, independent of obesity-
related traits, such as insulin and visceral fat [17].
The primary aim of the current study is to replicate
the effect of magnesium citrate on arterial stiffness that
we found in our previous study. Secondly, we aim to test
whether magnesium oxide and magnesium sulfate are
noninferior to the effect of magnesium citrate on arterial
stiffness and to unravel possible underlying mechanisms,




In this randomized, double-blind, placebo-controlled trial,
healthy overweight and slightly obese volunteers will be
allocated to one of the three magnesium groups or the pla-
cebo control group. This study will be conducted at the
University Medical Center Groningen (UMCG). The
current protocol was written in accordance with the Stand-
ard Protocol Items: Recommendations for Interventional
Trials (SPIRIT) guideline (Fig. 1 and Additional file 1) [18].
Ethics committee approval was obtained from the UMCG,
the Netherlands.
Characteristics of participants
For the present study, only subjects who provide written
informed consent are eligible. Furthermore, participants
should be between 45 and 75 years and should be over-
weight or slightly obese (body mass index between 25 and
35 kg/m2), because these subjects are expected to have
increased arterial stiffness and blood pressure at baseline,
allowing for improvement by the intervention [19]. To avoid
any possible variations in the study outcomes due to hor-
monal effects, only postmenopausal women (≥ 2 years after
last menstruation) will be included. Participants who meet
any of the following criteria are not eligible for this study:
– high magnesium intake (defined as urinary
magnesium excretion of ≥ 7.0 or ≥ 5.9 mmol/24 h
for men and women, respectively);
– plasma glucose ≥ 7.0 mmol/l;
– serum total cholesterol ≥ 8.0 mmol/l;
– serum triglycerides ≥ 2.2 mmol/l;
– current smoker or smoking cessation < 12 months;
– presence of diabetes mellitus;
– familial hypercholesterolemia;
– abuse of drugs;
– more than 21 alcoholic consumptions per week;
– unstable body weight (weight gain or loss > 3 kg
in the past 3 months);
– use of proton pump inhibitors;
– use of lipid-lowering drugs and/or antihypertensive
therapy that started in the past 6 months;
– use of magnesium supplements or an investigational
product within another biomedical within the
previous 1 month;
– severe medical conditions that might interfere with
the study, such as epilepsy, asthma, kidney failure or
renal insufficiency, chronic obstructive pulmonary
disease, inflammatory bowel diseases,
autoinflammatory diseases and rheumatoid arthritis;
– active cardiovascular disease; or
– not willing to give up being a blood donor
(or having donated blood) from 8 weeks before the
start of the study and during the study.
Interventions
The overweight and slightly obese participants will be ran-
domly assigned to receive: magnesium citrate; magnesium
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oxide; magnesium sulfate; or placebo. A flow chart of the
study interventions is presented in Fig. 2. Study parti-
cipants will be requested to take 2 capsules thrice daily for
24 weeks. On the test days, the first 2 capsules will be
taken after all measurements are completed. Each magne-
sium supplement provides 75mg magnesium (Magnesium
Citrate Complex (Mg 15.5%) Magnesium Sulphate Com-
plex (17.4%) and Magnesium Oxide Complex (60.3%);
AMT Laboratories Inc.). Thus, daily magnesium intake
provided by the 6 capsules will be 450mg. The placebo
capsules will contain starch (Amylum solani). The total
treatment duration of 24 weeks is based on our previous
study that showed a significant effect of magnesium
supplementation on arterial stiffness after 24 weeks [9]. At
baseline and weeks 2, 12 and 24, participants will undergo
PWVc–f, office blood pressure and body composition
measurements. Prior to each test day, participants will
collect 24-h urine and fecal samples. In addition, partici-
pants will be requested to complete the Patient Health
Questionnaire (PHQ-15) before each test day. The PHQ-
15 is a somatic symptom subscale derived from the full
PHQ. This questionnaire includes about 15 somatic symp-
toms or symptom clusters that account for more than
90% of the physical complaints reporting in the outpatient
setting [20]. Finally, subjects will record any signs of illness
in diaries, as well as medication used, and any deviations
from the protocol during the study. Subjects are requested
not to change their physical activity level, their food intake
pattern or use of alcohol during the entire study.
Blinding and randomization
To ensure the double-blind design, optically similar cap-
sules will be packed and coded by laboratory Medisan
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Fig. 1 Schedule of enrolment, interventions and assessment. PWVc–f carotid-to-femoral pulse wave velocity, PHQ-15 Patient Health Questionnaire
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medication (magnesium supplements and placebo). In
addition, this laboratory will conduct the randomization
procedure. For this, they will create a categorical list in
logical order. This list will include one intervention for
each subject. Based on a computer-generated list of
random number, subjects will be randomized into one
of the groups. This results in a randomized list of treat-
ment allocation.
Sample size calculation
The current study is powered on arterial stiffness, the pri-
mary endpoint. The required sample size for noninferio-
rity testing is calculated based on a margin of 0.5 m/s, a
probability of 0.05 and a power of 0.80. Therefore, 41
subjects per magnesium group are needed. To compare
magnesium citrate with placebo, we assume that the num-
ber of subjects per group calculated for a two-arm trial (n
= 24) is sufficient. Because a 10% dropout rate is expected,
162 will be recruited to start the study. By taking into ac-
count that only 50% of the subjects included in the screen-
ing will meet all inclusion criteria and are willing to
participate, 324 subjects are expected to participate in the
screening visits.
This sample size calculation is based on an intra-
subject variability of 0.9 m/s and a 1.0 m/s change in the
PWVc–f after 24 weeks of magnesium supplementation
found in our previous study [9]. The equivalence margin
of 0.5 m/s is based on the observed effect [9], which is
50% of the magnesium citrate supplementation effect
compared to placebo. For the calculation of the sample
size, the formula of Julious [21] was used.
Compliance to the intervention
Compliance will be assessed based on the number of
returned capsules after 12 and 24weeks. Subjects will be
considered compliant when they take at least 80% of the
capsules. In addition, we will assess compliance by urinary
magnesium concentrations at the end of the study.
Main outcome
The PWVc–f will be recorded in duplicate using the
SphygmoCor v9 (AtCor Medical, West Ryde, Australia).
First, the distance from the suprasternal notch to the
femoral recording site (via umbilicus) will be measured
[22]. Subsequently, the distance from the suprasternal
notch to the carotid recording site (right) will be subtracted.
Fig. 2 Flow chart of the study design
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In addition, the direct distance between the carotid record-
ing site and the femoral recording site (right) will be
measured. Second, ECG electrodes will be applied in
order to identify the R-wave in the ECG complex. Then,
using the tonometer, the arrival of the pulse wave and
the delay to the R-wave of the ECG will be measured at
the carotid and femoral arteries. If all correct measures
are entered and recorded, the program of the manufac-
turer will calculate the PWVc–f automatically. Using the
same tonometer applied to the radial artery near the wrist
of the right arm, pulse wave analysis (PWA) will be deter-
mined. Measurements are synchronized beat to beat and
will be recorded in duplicate. From these recordings, the
program of the manufacturer will determine the central




Office blood pressure (systolic and diastolic) and heart
rate will be monitored using a continuous blood pressure
monitoring device (Criticare 506 N3; Criticare Systems
Inc., Waukesha, WI, USA). The investigator will measure
the blood pressure before the PWVc–f measurements.
After an acclimatization period of at least 15min in the
supine position, office blood pressure will be measured.
The first measurement will be discarded, and the mean of
the last three measurements will be reported [23].
Gut microbiota
Subjects will be asked to collect a fecal sample 1 or 2 days
prior to the test day and store the sample in the fridge at
home. They will be asked to bring the sample to the
UMCG on ice (cooling elements or in a bag with ice
cubes). On the test day, the samples will be immediately
stored at − 80 °C. We will investigate the microbiome
diversity, specific operational taxonomy as well as specific
circulating metabolites, including phenylacetylglutamine,
trimethylamine oxide (TMAO) and indoleproprionate
(IPA), which have been previously linked to cardiovascular
events and metabolic syndrome, respectively [24, 25]. The
composition of the gut microbiota in fecal samples will be
analyzed with PCR amplification of the 16S rRNA V4–V5
variable region and deep sequencing using the Illumina®
MiSeq platform.
Anthropometric measurements
On each test day, anthropometric measurements (body
weight without shoes and heavy clothing and body com-
position) will be performed to characterize participants.
Body composition (e.g. fat mass, lean body mass, extra-
cellular water and intracellular water) will be measured by
Bio-Electrical Impedance Analysis (Bodystat Quadscan
4000®; Quadscan, Douglas, Isle of Man, UK). The
measurements will be carried out with the patient in the
supine position for 5min, with their arms parallel to and
separated from the trunk and their legs apart. The elec-
trode sites will be cleaned with an alcohol wipe. Two elec-
trodes will be placed on the right hand and wrist, and
another two on the right foot and ankle.
Patient Health Questionnaire
Participants will be requested to complete the Patient
Health Questionnaire (PHQ-15) before each test day.
The PHQ-15 is a somatic symptom subscale derived
from the full PHQ. This questionnaire includes about 15
somatic symptoms or symptom clusters that account for
more than 90% of the physical complaints reporting in
the outpatient setting [20].
Clinical chemistry
Blood samples will be analyzed at the Department of
Laboratory Medicine of the UMCG, according to routine
procedures: plasma levels of magnesium, sodium, po-
tassium, chloride, calcium, phosphate, urea, total pro-
tein, albumin, creatinine and hemoglobin, hematocrit,
leukocytes, thrombocytes and metabolic risk markers
(triglycerides, total cholesterol, LDL-cholesterol and
HDL-cholesterol, fasting plasma glucose and HbA1C) will
be measured. In addition, urinary calcium, sodium, po-
tassium, chloride and creatinine will be determined. To
determine the magnesium status, plasma magnesium
levels and intra-erythrocyte magnesium will be measured
according to routine procedures.
Dietary intake
To ensure that participants have maintained their food
pattern during the study, subjects are asked to report
their diet for 3 consecutive days at the start and at the
end of the study in dietary diaries using standard supply
units [26]. These diaries will be checked for complete-
ness by the investigator.
Statistical analysis
For normally distributed parameters, data will be pre-
sented as the mean value and standard deviation. Non-
normally distributed parameters will be presented as the
median (range). For statistical analyses, responses will be
calculated defined as the difference between follow-up
and baseline values. For the primary analyses, in which
the effect of magnesium citrate on arterial stiffness will be
evaluated, differences in responses between magnesium
citrate and placebo will be tested (one-factor ANCOVA)
with use of the baseline measurements of the outcome
variables as covariates. In order to test as secondary
analyses whether the effect of magnesium oxide and
magnesium sulfate on arterial stiffness are noninferior to
the effect of magnesium citrate on arterial stiffness, a
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noninferiority margin (Δ) of 0.5 m/s is chosen based on
the effect size of magnesium citrate on arterial stiffness
found in previous research [9]. A one-factor ANCOVA,
with use of the baseline measurements of the outcome
variables as covariates, will be conducted to evaluate
differences in responses between magnesium and placebo
treatments. To prove noninferiority, the lower limit of the
confidence interval of the difference between magnesium
sulfate and magnesium citrate and the difference between
magnesium oxide and magnesium citrate must not exceed
the limit of Δ to be 95% sure that magnesium oxide and
magnesium sulfate are not worse than magnesium citrate
supplements by more than Δ. Treatment effects will be
calculated at each time point (after 2, 12 and 24 weeks)
with one-factor ANCOVA. Differences are considered
statistically significant at P < 0.01 for the primary analyses
(confirmatory) and P < 0.05 for the secondary analyses
(exploratory). Statistical analyses will be performed using
SPSS 23.0 software for Windows (SPSS Incorporated,
Chicago, IL, USA). Normality of the residuals will be
examined using the Shapiro–Wilk normality test. If a
residual is not normally distributed, parameters will be
log-transformed. If after log-transformation the residuals
are still not normally distributed, nonparametric tests will
be used. Missing data will not be replaced by estimates.
Because of randomization, it is expected that confounders
will be divided equally. Therefore, no adjustment for con-
founding will take place. The intention-to-treat principle
will be applied in primary analyses. Secondly, we will con-
duct per-protocol analyses (exclude noncompliance sub-
jects from the statistical analysis). To prove noninferiority,
the confidence interval of the difference must exclude the
margin in both the intention-to-treat and the per-protocol
analyses. Finally, we will conduct subgroup analyses
in which we will compare the effects of magnesium
on arterial stiffness in subjects on antihypertensive
therapy and subjects not on antihypertensive therapy.
Because over time arterial stiffness may increase
more rapidly in subjects treated for hypertension, our
hypothesis is that magnesium may have a more pro-
nounced effect on arterial stiffness in subjects on
antihypertensive therapy.
Discussion
The current study aims to replicate the effect of magne-
sium citrate on arterial stiffness that we found in our
previous study [9], now with a slightly higher dose and
to evaluate whether magnesium oxide and magnesium
sulfate are noninferior to the effect of magnesium citrate
in terms of arterial stiffness. We furthermore aim to un-
ravel possible underlying mechanisms, including changes
in blood pressure and gut microbiota diversity. To our
knowledge, this is the first clinical trial that compares the
long-term effects of different commercially available
magnesium supplements on well-established cardiovascu-
lar risk markers, including arterial stiffness, blood pressure
and gut microbiota [27–29]. Results of longitudinal epide-
miologic studies have found that a decrease of 1.0 m/s in
arterial stiffness, measured by the PWVc–f, corresponded
to a reduced risk of cardiovascular events of 14% [30],
underlining the potential clinical relevance of mag-
nesium supplementation in the prevention of cardio-
vascular disease.
So far, only three studies have addressed the effect of
magnesium supplementation on arterial stiffness [9, 31,
32]. Cunha et al. [31] reported an effect on blood pressure
and endothelial function in hypertensive women after
magnesium supplementation. However, no effect on
arterial stiffness was found. Furthermore, the study by
Cosaro et al. [32] showed neither an effect on blood
pressure nor on arterial stiffness. Of note, the magne-
sium formulation, total daily dose, trial duration and
study design were different between these studies. No
studies have performed a head-to-head comparison
between various magnesium formulations. Particularly,
the difference between organic and inorganic formu-
lations may be of interest.
It has been suggested that organic magnesium formu-
lations (e.g. magnesium citrate) are superior to inorganic
magnesium formulations, such as magnesium oxide, in
terms of bioavailability [33, 34]. However, a meta-
analysis of 34 clinical trials demonstrated that indivi-
duals supplemented with inorganic compounds, mainly
with chloride as the counterbalancing anion, showed
higher serum magnesium levels and more pronounced
blood pressure reduction compared to organic com-
pounds [35]. A total daily dose of 450 mg was chosen,
because previous clinical trials showed a greater blood
pressure-lowering response when the total daily dose of
magnesium was increased [35].
In conclusion, the present study is expected to provide
evidence for the effects of different commercially available
magnesium formulations (organic and inorganic) on well-
established cardiovascular risk markers, including arterial
stiffness and blood pressure, as well as on the human gut
microbiota. The total daily dose of magnesium in the
current study is based on previous meta-analyses that
reported greater efficacy at higher dosages. Based on
dietary recommendations and current evidence, together
with the good safety profile of magnesium supplements
and the low rate of adverse events so far reported by
previous studies, no risks are expected after a daily supple-
ment of 450mg in the form of magnesium citrate, mag-
nesium oxide and magnesium sulfate.
Trial status
The trial is ongoing. Approximately 100 subjects have
been included in the study at the time of submission.
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Additional subjects needed for the study will be
recruited by advertisements in newspapers. The
recruitment of participants for this study began in
September 2017, and is presently ongoing. Re-
cruitment is expected to be completed by the end
of 2019.
Additional file
Additional file 1: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents (DOC 120 kb)
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